The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan

Hepatology

Volumn 56, Issue 4, 2012, Pages 1223-1230

  Russell, Marcia ^a   Pauly, Mary Patricia ^b   Moore, Charles Denton ^b   Chia, Constance ^b   Dorrell, Jennifer ^b   Cunanan, Renee J ^b   Witt, Gayle ^b   Martin, Scott ^a  

^a PREVENTION RESEARCH CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ARTICLE; DRINKING BEHAVIOR; ETHNICITY; FEMALE; GENOTYPE; HEALTH CARE PLANNING; HEALTH INSURANCE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALCOHOL DRINKING; ANTIVIRAL AGENTS; CALIFORNIA; COHORT STUDIES; CONFIDENCE INTERVALS; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INSURANCE, HEALTH; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYETHYLENE GLYCOLS; PRIVATE SECTOR; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867178291     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25755     Document Type: Article

References (22)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521.e511-516.
4. Tsui JI, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci 2008; 54: 2694-2698.
5. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955-963.
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
7. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. HEPATOLOGY 2008; 47: 1128-1135.
8. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. J Gen Intern Med 2005; 20: 754-758.
9. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-1616.
10. Russell M, Marshall JR, Trevisan M, Freudenheim JL, Chan AW, Markovic N, et al. Test-retest reliability of the cognitive lifetime drinking history. Am J Epidemiol 1997; 146: 975-981.
11. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Helping Patients Who Drink Too Much: A Clinicians' Guide, Updated 2005 Edition. Washington, DC: National Institute on Alcohol Abuse and Alcoholism; 2005.
12. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-1379.
13. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039-1043.
14. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20: 371A-377A.
15. Loguercio C, Di Pierro M, Di Marino MP, Federico A, Disalvo D, Crafa E, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological, and pathological aspects. Alcohol Alcohol 2000; 35: 296-301.
16. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9: 288-294.
17. Chang A, Skole K, Gautam M, Schmutz J, Black M, Thomas R, et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 22: 701-706.
18. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850.
19. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001; 286: 1715-1723.
20. Czarnecki DM, Russell M, Cooper ML, Salter D. Five-year reliability of self-reported alcohol consumption. J Stud Alcohol 1990; 51: 68-76.
21. Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in pregnancy. Alcohol Clin Exp Res 1988; 12: 506-511.
22. Simpura J, Poikolainen K. Accuracy of retrospective measurement of individual alcohol consumption in men: a reinterview after 18 years. J Stud Alcohol 1983; 44: 911-917.